Here, we demonstrate that all peptides were immunogenic and are able to induce anti-tumor immune responses against FJX1-expressing head and neck cancer cells, suggesting that FJX1 specific peptides could be efficacious and a viable therapy for the treatment of head and neck cancers including NPC. Here, FJX1 is linked to nasopharyngeal carcinoma.